Brachytherapy boost after chemoradiation in anal cancer: A systematic review

Rezarta Frakulli, Milly Buwenge, Silvia Cammelli, Gabriella Macchia, Eleonora Farina, Alessandra Arcelli, Martina Ferioli, Lorenzo Fuccio, Luca Tagliaferri, Andrea Galuppi, Giovanni P. Frezza, Alessio G. Morganti

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC. A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included. Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6% (range, 70.7-92.0%), 76.1% (range, 61.4-86.4%), 75.8% (range, 65.9-85.7%), and 69.4% (63.4-82.0%), respectively. The reported toxicities were acceptable. RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalJournal of Contemporary Brachytherapy
Volume10
Issue number3
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Anus Neoplasms
Brachytherapy
Colostomy
Radio
Disease-Free Survival
Survival
Bibliographic Databases
Radiation
Drug Therapy
PubMed
Libraries
Therapeutics
Randomized Controlled Trials
Retrospective Studies

Keywords

  • Anal cancer
  • Brachytherapy boost
  • Systematic review

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Frakulli, R., Buwenge, M., Cammelli, S., Macchia, G., Farina, E., Arcelli, A., ... Morganti, A. G. (2018). Brachytherapy boost after chemoradiation in anal cancer: A systematic review. Journal of Contemporary Brachytherapy, 10(3), 246-253. https://doi.org/10.5114/jcb.2018.76884

Brachytherapy boost after chemoradiation in anal cancer : A systematic review. / Frakulli, Rezarta; Buwenge, Milly; Cammelli, Silvia; Macchia, Gabriella; Farina, Eleonora; Arcelli, Alessandra; Ferioli, Martina; Fuccio, Lorenzo; Tagliaferri, Luca; Galuppi, Andrea; Frezza, Giovanni P.; Morganti, Alessio G.

In: Journal of Contemporary Brachytherapy, Vol. 10, No. 3, 01.01.2018, p. 246-253.

Research output: Contribution to journalReview article

Frakulli, R, Buwenge, M, Cammelli, S, Macchia, G, Farina, E, Arcelli, A, Ferioli, M, Fuccio, L, Tagliaferri, L, Galuppi, A, Frezza, GP & Morganti, AG 2018, 'Brachytherapy boost after chemoradiation in anal cancer: A systematic review', Journal of Contemporary Brachytherapy, vol. 10, no. 3, pp. 246-253. https://doi.org/10.5114/jcb.2018.76884
Frakulli R, Buwenge M, Cammelli S, Macchia G, Farina E, Arcelli A et al. Brachytherapy boost after chemoradiation in anal cancer: A systematic review. Journal of Contemporary Brachytherapy. 2018 Jan 1;10(3):246-253. https://doi.org/10.5114/jcb.2018.76884
Frakulli, Rezarta ; Buwenge, Milly ; Cammelli, Silvia ; Macchia, Gabriella ; Farina, Eleonora ; Arcelli, Alessandra ; Ferioli, Martina ; Fuccio, Lorenzo ; Tagliaferri, Luca ; Galuppi, Andrea ; Frezza, Giovanni P. ; Morganti, Alessio G. / Brachytherapy boost after chemoradiation in anal cancer : A systematic review. In: Journal of Contemporary Brachytherapy. 2018 ; Vol. 10, No. 3. pp. 246-253.
@article{dd68bf989b8c46f69d99e91863141172,
title = "Brachytherapy boost after chemoradiation in anal cancer: A systematic review",
abstract = "Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC. A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included. Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6{\%} (range, 70.7-92.0{\%}), 76.1{\%} (range, 61.4-86.4{\%}), 75.8{\%} (range, 65.9-85.7{\%}), and 69.4{\%} (63.4-82.0{\%}), respectively. The reported toxicities were acceptable. RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.",
keywords = "Anal cancer, Brachytherapy boost, Systematic review",
author = "Rezarta Frakulli and Milly Buwenge and Silvia Cammelli and Gabriella Macchia and Eleonora Farina and Alessandra Arcelli and Martina Ferioli and Lorenzo Fuccio and Luca Tagliaferri and Andrea Galuppi and Frezza, {Giovanni P.} and Morganti, {Alessio G.}",
year = "2018",
month = "1",
day = "1",
doi = "10.5114/jcb.2018.76884",
language = "English",
volume = "10",
pages = "246--253",
journal = "Journal of Contemporary Brachytherapy",
issn = "1689-832X",
publisher = "Termedia Publishing House Ltd.",
number = "3",

}

TY - JOUR

T1 - Brachytherapy boost after chemoradiation in anal cancer

T2 - A systematic review

AU - Frakulli, Rezarta

AU - Buwenge, Milly

AU - Cammelli, Silvia

AU - Macchia, Gabriella

AU - Farina, Eleonora

AU - Arcelli, Alessandra

AU - Ferioli, Martina

AU - Fuccio, Lorenzo

AU - Tagliaferri, Luca

AU - Galuppi, Andrea

AU - Frezza, Giovanni P.

AU - Morganti, Alessio G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC. A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included. Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6% (range, 70.7-92.0%), 76.1% (range, 61.4-86.4%), 75.8% (range, 65.9-85.7%), and 69.4% (63.4-82.0%), respectively. The reported toxicities were acceptable. RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.

AB - Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC. A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included. Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6% (range, 70.7-92.0%), 76.1% (range, 61.4-86.4%), 75.8% (range, 65.9-85.7%), and 69.4% (63.4-82.0%), respectively. The reported toxicities were acceptable. RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.

KW - Anal cancer

KW - Brachytherapy boost

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85052405284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052405284&partnerID=8YFLogxK

U2 - 10.5114/jcb.2018.76884

DO - 10.5114/jcb.2018.76884

M3 - Review article

AN - SCOPUS:85052405284

VL - 10

SP - 246

EP - 253

JO - Journal of Contemporary Brachytherapy

JF - Journal of Contemporary Brachytherapy

SN - 1689-832X

IS - 3

ER -